Q3 EPS Forecast for United Therapeutics Increased by Analyst

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Research analysts at Leerink Partnrs upped their Q3 2025 earnings per share estimates for United Therapeutics in a research note issued on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will earn $8.50 per share for the quarter, up from their prior estimate of $8.08. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics' FY2025 earnings at $29.96 EPS, FY2026 earnings at $30.99 EPS, FY2027 earnings at $30.46 EPS and FY2028 earnings at $31.87 EPS.

Several other equities research analysts have also recently commented on UTHR. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a research report on Monday, April 21st. Cantor Fitzgerald began coverage on United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective on the stock. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Finally, Morgan Stanley increased their price objective on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $393.00.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded up $2.58 during trading on Friday, reaching $328.40. 541,269 shares of the stock traded hands, compared to its average volume of 439,644. The stock has a 50-day moving average of $301.06 and a two-hundred day moving average of $333.13. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a market cap of $14.81 billion, a P/E ratio of 14.42, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same quarter in the prior year, the company posted $6.17 earnings per share. The business's revenue for the quarter was up 17.2% on a year-over-year basis.

Insider Activity

In related news, Director Raymond Dwek sold 4,000 shares of United Therapeutics stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the sale, the director now owns 1,750 shares of the company's stock, valued at approximately $497,962.50. This trade represents a 69.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,500 shares of company stock valued at $16,923,950 in the last ninety days. Corporate insiders own 10.30% of the company's stock.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently bought and sold shares of UTHR. Wealthfront Advisers LLC grew its stake in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after acquiring an additional 18,313,424 shares in the last quarter. Norges Bank bought a new stake in United Therapeutics in the 4th quarter worth approximately $151,764,000. FMR LLC increased its stake in United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after acquiring an additional 393,777 shares during the last quarter. Vaughan Nelson Investment Management L.P. bought a new stake in United Therapeutics in the 1st quarter worth approximately $101,354,000. Finally, Nuveen LLC bought a new stake in United Therapeutics in the 1st quarter worth approximately $83,533,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.